IP Library Granted Patent US 8,227,516
Granted Patent B2
US 8,227,516 · App. 11/778,297 · Granted Jul 24, 2012

Compounds as histone deacetylase inhibitors

Assignee: 4SC Discovery GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,227,516
App. No.
11/778,297
Granted
Jul 24, 2012
Kind
B2
Abstract

The present invention relates to compounds as inhibitors of enzymes having histone deacetylase activity, to the processes for the preparation of those compounds, and to their use for the treatment of diseases which are associated with hypoacetylation of histones and/or other molecules, or in which induction of hyperacetylation has a beneficial effect for example by inhibition of proliferation and/or induction of differentiation and/or induction of apoptosis in transformed cells, such as cancer. Furthermore, the compounds are useful for the treatment of other proliferative diseases, for therapy or prophylaxis of conditions associated with abnormal gene expression.

Claims (13)

1. A method of treating an inflammatory disorder, diabetes, or cirrhosis in a subject in need thereof, comprising administering to said subject an effective amount of a compound of formula (I):

or a pharmaceutically acceptable salt or a physiologically functional derivative thereof wherein:

the ring n including Z is selected from the group consisting of cyclopentyl and cyclohexyl;

X is CH 2 or, if the dotted line at X represents a double bond, X is CH,

Y is selected from the group consisting of CH, CH 2 , CH 2 —CH 2 ;

p is 0 or 1;

wherein the physiologically functional derivative is selected from the group consisting of ethers, esters, N-alkylated or acetylated hydroxamic acids, 2,5-dihydro-[1,2,4]oxodiazolyl or 4,5-dihydro-[1,2,4]-oxadiazolyls of the compound of formula (I); and

with the proviso that the following compounds are excluded:

2. A method of treating an inflammatory disorder, diabetes or cirrhosis in a subject in need thereof, comprising:

administering an effective amount of a pharmaceutical composition to a subject in need thereof, thereby inhibiting abnormal gene expression characteristic of inflammatory disorders, diabetes, or cirrhosis, the pharmaceutical composition comprising a compound as defined in claim 1 in free from or in the form of a pharmaceutically acceptable salt or a physiologically acceptable derivative thereof, and a pharmaceutically acceptable excipient.

3. A method according to claim 1 , wherein the compound is 3 Cyclohexyl-N-hydroxy-propionamide.

4. A method according to claim 1 , wherein the compound is 3-Cyclohexyl-N-hydroxy-acrylamide.

5. A method of treating an inflammatory disorder, diabetes, or cirrhosis in a subject in need thereof, comprising administering to said subject an effective amount of 3-Cyclopentyl-N-hydroxy-propionamide.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2012
From: 4SC AG
To: 4SC DISCOVERY GMBH
Reel/Frame 028136/0359 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2012
From: TOPOTARGET GERMANY AG
To: 4SC AG
Reel/Frame 028136/0437 →
CHANGE OF NAME Recorded May 1, 2012
From: G2M CANCER DRUGS AG
To: TOPOTARGET GERMANY AG
Reel/Frame 028136/0576 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2008
From: MAURER, ALEXANDER B.; HOEVELMANN, SASCHA; MARTIN, ELKE; HENTSCH, BERND; GASSEN, MICHAEL; KRAUS, JUERGEN; KRAUSS, ROLF; VINCEK, ADAM-SPENCER
To: 4SC AG; G2M CANCER DRUGS AG
Reel/Frame 021251/0418 →
Continuity (3)
Division 10624571 · Jul 23, 2003
Provisional Application 60397663 · Jul 23, 2002
Related Publication 20090088478A1 · Apr 2, 2009